Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation

Abstract EN

Purpose.

To assess the cost-effectiveness of bevacizumab compared to ranibizumab, verteporfin photodynamic therapy (PDT), and usual care for the treatment of age-related macular degeneration (AMD) in China.

Methods.

A Markov model was developed according to patient visual acuity (VA) in the better-seeing eye (Snellen scale).

Four cohorts of patients were treated with one of the following therapies: bevacizumab, ranibizumab, PDT, or usual care.

Clinical data related to treatments were obtained from published randomized clinical trials.

Direct medical costs and resource utilization in the Chinese health care setting were taken into account.

Health and economic outcomes were evaluated over a lifetime horizon.

Sensitivity analyses were performed.

Results.

Treatment with ranibizumab provided the greatest gains in quality-adjusted life-years (QALYs).

The cost per marginal QALY gained with bevacizumab over usual care was $1,258, $3,803, and $2,066 for the predominantly classic, minimally classic, and occult lesions, respectively.

One-way sensitivity analysis showed considerably influential factors, such as utility values and effectiveness data.

Probabilistic sensitivity analysis indicated that, compared to usual care, PDT and ranibizumab most cases would be cost-effective in the bevacizumab arm at a threshold of $7,480/QALY.

Conclusion.

Bevacizumab can be a cost-effective option for the treatment of AMD in the Chinese setting.